128 related articles for article (PubMed ID: 36841969)
1. Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients.
Torous DK; Avlasevich S; Bemis JC; Howard T; Ware RE; Fung C; Chen Y; Sahsrabudhe D; MacGregor JT; Dertinger SD
Environ Mol Mutagen; 2023 Mar; 64(3):167-175. PubMed ID: 36841969
[TBL] [Abstract][Full Text] [Related]
2. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Ware RE; Dertinger SD
Br J Haematol; 2021 Jul; 194(2):252-266. PubMed ID: 33570176
[TBL] [Abstract][Full Text] [Related]
3. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.
Flanagan JM; Howard TA; Mortier N; Avlasevich SL; Smeltzer MP; Wu S; Dertinger SD; Ware RE
Mutat Res; 2010 Apr; 698(1-2):38-42. PubMed ID: 20230905
[TBL] [Abstract][Full Text] [Related]
4. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia.
Vinhaes CL; Teixeira RS; Monteiro-Júnior JAS; Tibúrcio R; Cubillos-Angulo JM; Arriaga MB; Sabarin AG; de Souza AJ; Silva JJ; Lyra IM; Ladeia AM; Andrade BB
Sci Rep; 2020 Nov; 10(1):18982. PubMed ID: 33149225
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
8. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
[TBL] [Abstract][Full Text] [Related]
9. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
[TBL] [Abstract][Full Text] [Related]
10. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.
Sheehan VA; Crosby JR; Sabo A; Mortier NA; Howard TA; Muzny DM; Dugan-Perez S; Aygun B; Nottage KA; Boerwinkle E; Gibbs RA; Ware RE; Flanagan JM
PLoS One; 2014; 9(10):e110740. PubMed ID: 25360671
[TBL] [Abstract][Full Text] [Related]
11. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
12. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
DeBaun MR
Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps.
Dong M; Ware RE; Dallmann A; Vinks AA
Pharmacotherapy; 2023 May; 43(5):419-429. PubMed ID: 36928875
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
16. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
Chambers TM; Kahan S; Camanda JF; Scheurer M; Airewele GE
Pediatr Blood Cancer; 2018 Dec; 65(12):e27365. PubMed ID: 30051651
[TBL] [Abstract][Full Text] [Related]
17. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype.
da Silva Rocha LB; Dias Elias DB; Barbosa MC; Bandeira IC; Gonçalves RP
Mutat Res; 2012 Dec; 749(1-2):48-52. PubMed ID: 22918118
[TBL] [Abstract][Full Text] [Related]
18. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
Heeney MM; Howard TA; Zimmerman SA; Ware RE
J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
[TBL] [Abstract][Full Text] [Related]
19. Acquired DNA mutations associated with in vivo hydroxyurea exposure.
Hanft VN; Fruchtman SR; Pickens CV; Rosse WF; Howard TA; Ware RE
Blood; 2000 Jun; 95(11):3589-93. PubMed ID: 10828048
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?
McGann PT; Ware RE
Curr Opin Hematol; 2011 May; 18(3):158-65. PubMed ID: 21372708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
